(PRNB) – Company Press Releases
-
Patient Enrollment Concluded Early in PEGASUS Phase 3 Pemphigus Trial for Rilzabrutinib
-
Neoleukin Therapeutics Announces Third Quarter 2020 Financial Results and Corporate Update
-
Principia Announces First Patient Dosed in Phase 2A Trial of Rilzabrutinib in IgG4-Related Disease
-
Principia Announces First Patient Dosed in Phase 2A Trial of Rilzabrutinib in IgG4-Related Disease
-
Neoleukin Therapeutics Announces Appointment of Martin Babler to Board of Directors
-
Neoleukin Therapeutics Announces Appointment of Martin Babler to Board of Directors
-
MERGER ALERT – CGIX, PRNB, and MNTA: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
-
MERGER ALERT - NTN, PRNB, and CBMG: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
-
Sanofi to acquire Principia Biopharma
-
Principia Biopharma Reports Second Quarter 2020 Financial Results
-
Principia Biopharma Reports Second Quarter 2020 Financial Results
-
Principia Announces First Patient Enrolled in Sanofi’s Phase 3 Trial of SAR442168 in Relapsing Multiple Sclerosis
-
Principia Announces First Patient Enrolled in Sanofi’s Phase 3 Trial of SAR442168 in Relapsing Multiple Sclerosis
-
Principia Announces Positive Data from its Phase 2 Part B Trial in Pemphigus
-
Principia Announces Positive Data from its Phase 2 Part B Trial in Pemphigus
-
Principia Presents Updated Positive Data of Rilzabrutinib for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial
-
Principia Presents Updated Positive Data of Rilzabrutinib for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial
-
Principia Biopharma to Hold Virtual Analyst Event to Discuss BTK Inhibition: Beyond B Cells and Antibodies
-
Principia Biopharma to Hold Virtual Analyst Event to Discuss BTK Inhibition: Beyond B Cells and Antibodies
-
Principia Announces Data Presentations of Rilzabrutinib in Patients with Immune Thrombocytopenia (ITP) at Two Upcoming Virtual Medical Meetings
-
Principia Announces Data Presentations of Rilzabrutinib in Patients with Immune Thrombocytopenia (ITP) at Two Upcoming Virtual Medical Meetings
-
Principia Announces AAD Late Breaker Research Presentation of its Pemphigus Phase 2 Part B Trial
-
Principia Announces AAD Late Breaker Research Presentation of its Pemphigus Phase 2 Part B Trial
-
Principia Biopharma Reports First Quarter 2020 Financial Results
-
Principia Biopharma Reports First Quarter 2020 Financial Results
-
Principia Biopharma to Present at the 2020 Bank of America Health Care Conference
-
Principia Biopharma to Present at the 2020 Bank of America Health Care Conference
-
Principia Biopharma Reports Fourth Quarter and Full Year 2019 Financial Results
-
Principia Biopharma Reports Fourth Quarter and Full Year 2019 Financial Results
-
Principia to Present at 9th Annual SVB Leerink Global Healthcare Conference
-
Principia to Present at 9th Annual SVB Leerink Global Healthcare Conference
-
Principia Announces Expansion of its BTK Franchise with PRN473 Topical
-
Principia Announces Expansion of its BTK Franchise with PRN473 Topical
-
Principia Announces Expanded Development Program to Broaden BTK Footprint in Immune-Mediated Diseases
-
Principia Announces Expanded Development Program to Broaden BTK Footprint in Immune-Mediated Diseases
-
Principia Updates PRN1008 Pemphigus Clinical Program
-
Principia Updates PRN1008 Pemphigus Clinical Program
-
Principia Presents Consistent Positive Data of PRN1008 for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial
-
Principia Presents Consistent Positive Data of PRN1008 for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial
-
Principia to Present at the Stifel Healthcare Conference 2019
-
Principia to Present at the Stifel Healthcare Conference 2019
-
Principia Biopharma Reports Third Quarter Financial Results
-
Principia Biopharma Reports Third Quarter Financial Results
-
Principia Announces Pricing of Public Offering of Common Stock
-
Principia Announces Pricing of Public Offering of Common Stock
-
Principia Announces Proposed Public Offering of Common Stock
-
Principia Announces Proposed Public Offering of Common Stock
-
Principia Announces Positive Preliminary Data of PRN1008 for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial
-
Principia Announces Positive Preliminary Data of PRN1008 from its Ongoing Phase 2 Part B Trial in Pemphigus
-
Principia Biopharma Appoints Shawn Tomasello to Its Board of Directors
Back to PRNB Stock Lookup